The latest call
FetchingTwist Bioscience Corporation reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
$111.56-2.2%Nov 13 close
The latest quarter (ended September 30, 2026) is from Twist Bioscience’s earnings press release of November 12, 2026. It will be replaced by the official annual report (10-K) once Twist Bioscience files it.
Company outlook: revenue of $130M to $132M for Fiscal Q1 2027 — up 26.3% on a year earlier
Just reported
From Twist Bioscience Corporation's results release of November 12, 2026. These are the company's first figures; its 10-Q or 10-K replaces them when filed.
Actual
$126.6M
+28% y/y
+7.0% q/q
Guided
—
No guide given
Actual
-$24.4M
Guided
—
No guide given
Q1 FY2027
| Measure | 3 months toSep 30, 2026 | 3 months toSep 30, 2025 | Change |
|---|---|---|---|
| Total Revenue | $126.6M | $99M | +27.91% |
| Profit | -$20.6M | -$27.1M | +24.01% |
These are single quarters, not a trailing year — the figures elsewhere on this site cover twelve months and will be much larger. A seasonal business swings a long way between the two: ServiceNow earns $2.0B of free cash flow in its December quarter and $0.5B in its June one.
Compared against the same quarter a year earlier, not against an analyst forecast. A “beat” or “miss” needs a consensus estimate, which is licensed data we do not carry — and getting it wrong is worse than leaving it out.
Twist Bioscience Corporation reported on November 12, 2026. We are fetching the call transcript; its summary follows once the transcript is in.
“Fiscal 2026 demonstrated what Twist can deliver: strong top line revenue growth, expanded gross margin and positive adjusted EBITDA in the fourth quarter, all while continuing to broaden our capabilities and strengthen our balance sheet,”
Quoted verbatim from the release, and shown only when the filing attributes it to a named person.
Releases land before the open or after the close, so the window runs from the close before the report day to the close of the session after it — the reaction is inside it either way.
Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets. We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries. Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all.
The company’s own description, as it appears at the foot of the release.
The quote, the company description and the latest quarter come from Twist Bioscience’s earnings press release (an Item 2.02 8-K) filed November 12, 2026. Earlier quarters come from its quarterly and annual reports, and the latest will be replaced once the official report is filed. Read the release on EDGAR Share prices are split- and dividend-adjusted.
Full year 2027
Set against the company's own guidance and the same quarter a year earlier, not analysts' estimates, which we do not hold. Adjusted figures are the company's own non-GAAP measures, as stated in the release.